The focus of the Molecular and Genomic Pathology Division is to provide Weill Cornell Medicine physicians with molecular information that will facilitate the diagnosis of diseases, monitor the prognosis of the patients and assist in the selection of appropriate therapeutic options. Our state-of-the-art facility uses innovative genomic technologies to interrogate and identify disease related entities in solid tumors, hematologic malignancies, infectious diseases and inherited diseases. Working closely with our clinicians, our mission is to provide molecular testing of the highest quality with a direct impact on patient care.
Click here to download our comprehensive test menu.
The Division of Molecular and Genomic Pathology at New York Presbyterian-Weill Cornell Medicine is comprised of three main entities: The Clinical Genomics, Molecular Pathology and Molecular Hematopathology Laboratories, all of which are CLIA-certified and accredited by New York State Department of Health (NYSDOH) and the College of American Pathologists (CAP).
The Clinical Genomics Laboratory offers genomic pathology services, in targeted and individualized care tailored to each patient based on his or her specific genetic profile and medical history. The genomic sequencing tests probe a patient’s genome to identify the specific genetic alterations that have resulted in the tumor. The laboratory is directed by James Solomon, MD, PhD.
The Molecular Hematopathology Laboratory performs molecular-based tests to aid in the diagnosis and management of hematologic cancers and offers expert consultation in specialized molecular testing for hematopathologists and clinical hematologists. The primary goal of the laboratory is to provide accurate molecular diagnostic information using modern technology to facilitate the delivery of excellent personalized health care to patients inflicted with hematologic malgnancies. The laboratory is directed by Michael Kluk, MD, PhD.
The Cytogenetics Laboratory at NewYork Presbyterian/Weill Cornell Medicine is an actively expanding diagnostic laboratory which processes annually about 4,500 samples / 12,500 tests including postnatal samples (peripheral blood and products of conception) as well as cancer specimens. The laboratory does conventional cytogenetics, fluorescence in situ hybridization (FISH) assays, and microarray on peripheral blood specimens.